Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
SCYX | US
0.01
0.70%
Healthcare
Drug Manufacturers-Specialty & Generic
30/06/2024
04/10/2024
1.44
1.44
1.48
1.41
SCYNEXIS Inc. a biotechnology company develops products for the treatment of fungal infections in the United States. It offers BREXAFEMME for the treatment of vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp an intravenous drug for the treatment of various fungal infections including invasive candidiasis refractory invasive fungal infections invasive aspergillosis VVC and recurrent VVC. It has research collaborations with Merck Sharp & Dohme Corp. Hansoh (Shanghai) Health Technology Co. Ltd. Jiangsu Hansoh Pharmaceutical Group Company Limited and R-Pharm CJSC to develop and commercialize rights for ibrexafungerp. The company was formerly known as SCYNEXIS Chemistry & Automation Inc. and changed its name to SCYNEXIS Inc. in June 2002. SCYNEXIS Inc. was incorporated in 1999 and is headquartered in Jersey City New Jersey.
View LessLow Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
Price Below SMA10D
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
Weak Operating Margin (< 10%)
Declining Revenue (< 0%)
Weak Sharpe Ratio (< 0.3)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
43.9%1 month
71.7%3 months
65.6%6 months
76.3%-
1.96
0.96
0.26
0.14
0.05
0.04
-
-51.34M
54.51M
54.51M
-
-1.26K
-
-99.40
-46.12
6.31
3.44
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
Range10D
0.23
Range1M
0.40
Range3M
1.03
Rel. volume
0.52
Price X volume
102.47K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Provectus Biopharmaceuticals Inc | PVCT | Drug Manufacturers-Specialty & Generic | 0.1014 | 42.58M | 4.54% | n/a | 0.00% |
DURECT Corporation | DRRX | Drug Manufacturers-Specialty & Generic | 1.24 | 38.49M | -7.46% | n/a | 318.92% |
India Globalization Capital Inc | IGC | Drug Manufacturers-Specialty & Generic | 0.3705 | 28.02M | -3.89% | n/a | 4.33% |
Lipocine Inc | LPCN | Drug Manufacturers-Specialty & Generic | 4.66 | 25.85M | 9.65% | n/a | 0.00% |
Flora Growth Corp. Common Stock | FLGC | Drug Manufacturers-Specialty & Generic | 1.56 | 20.85M | -8.77% | n/a | 76.81% |
MEI Pharma Inc | MEIP | Drug Manufacturers-Specialty & Generic | 2.81 | 18.72M | 2.18% | 1.09 | 0.00% |
Cumberland Pharmaceuticals Inc | CPIX | Drug Manufacturers-Specialty & Generic | 1.25 | 17.62M | 0.81% | n/a | 81.86% |
BGXX | BGXX | Drug Manufacturers-Specialty & Generic | 0.0365 | 7.16M | 1.11% | n/a | 5.20% |
Biofrontera Inc. Common Stock | BFRI | Drug Manufacturers-Specialty & Generic | 0.96 | 5.32M | -10.28% | n/a | 13.20% |
Universe Pharmaceuticals INC | UPC | Drug Manufacturers-Specialty & Generic | 0.2179 | 5.15M | -5.30% | n/a | 13.87% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
ILAG | ILAG | Building Products & Equipment | 1.0599 | 19.14M | -0.93% | n/a | 5.48% |
Antelope Enterprise Holdings Limited | AEHL | Building Products & Equipment | 0.695 | 8.47M | -4.15% | n/a | 16.03% |
Twin Vee PowerCats Co. Common Stock | VEEE | Recreational Vehicles | 0.6199 | 5.90M | 6.82% | n/a | 19.98% |
Forza X1 Inc | FRZA | Recreational Vehicles | 0.33 | 5.20M | 0.03% | n/a | 0.97% |
EZGO Technologies Ltd. Ordinary Shares | EZGO | Recreational Vehicles | 1.3899 | 3.55M | -0.01% | n/a | 9.62% |
Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 0.4859 | 2.44M | -9.19% | n/a | 0.00% |
Micromobility.com Inc. | MCOM | Recreational Vehicles | 0.01 | 913.02K | -1.96% | n/a | -37.05% |
Blackstone/GSO Senior Floating Rate Term Fund | BSL | Textile Manufacturing | 14.17 | 0 | 0.78% | n/a |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | 0.05 | 17.21 | Cheaper |
Ent. to Revenue | 0.04 | 334.38 | Cheaper |
PE Ratio | - | 26.92 | - |
Price to Book | 0.96 | 12.15 | Cheaper |
Dividend Yield | - | 2.77 | - |
Std. Deviation (3M) | 65.58 | 68.34 | Par |
Debt to Equity | 0.26 | -1.00 | Expensive |
Debt to Assets | 0.14 | 0.48 | Cheaper |
Market Cap | 54.51M | 5.31B | Emerging |